These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Population pharmacokinetics of hyperthermic intraperitoneal oxaliplatin in patients with peritoneal carcinomatosis after cytoreductive surgery. Pérez-Ruixo C; Valenzuela B; Peris JE; Bretcha-Boix P; Escudero-Ortiz V; Farré-Alegre J; Pérez-Ruixo JJ Cancer Chemother Pharmacol; 2013 Mar; 71(3):693-704. PubMed ID: 23274396 [TBL] [Abstract][Full Text] [Related]
4. Rate and extent of oxaliplatin absorption after hyperthermic intraperitoneal administration in peritoneal carcinomatosis patients. Pérez-Ruixo C; Peris JE; Escudero-Ortiz V; Bretcha-Boix P; Farré-Alegre J; Pérez-Ruixo JJ; Valenzuela B Cancer Chemother Pharmacol; 2014 May; 73(5):1009-20. PubMed ID: 24663502 [TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetic and pharmacodynamic analysis of hyperthermic intraperitoneal oxaliplatin-induced neutropenia in subjects with peritoneal carcinomatosis. Valenzuela B; Nalda-Molina R; Bretcha-Boix P; Escudero-Ortíz V; Duart MJ; Carbonell V; Sureda M; Rebollo JP; Farré J; Brugarolas A; Pérez-Ruixo JJ AAPS J; 2011 Mar; 13(1):72-82. PubMed ID: 21210260 [TBL] [Abstract][Full Text] [Related]
6. Safety of intraperitoneal Mitomycin C versus intraperitoneal oxaliplatin in patients with peritoneal carcinomatosis of colorectal cancer undergoing cytoreductive surgery and HIPEC. van Eden WJ; Kok NFM; Woensdregt K; Huitema ADR; Boot H; Aalbers AGJ Eur J Surg Oncol; 2018 Feb; 44(2):220-227. PubMed ID: 29258720 [TBL] [Abstract][Full Text] [Related]
7. Cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy with lobaplatin and docetaxel improves survival for patients with peritoneal carcinomatosis from abdominal and pelvic malignancies. Wu HT; Yang XJ; Huang CQ; Sun JH; Ji ZH; Peng KW; Zhang Q; Li Y World J Surg Oncol; 2016 Sep; 14(1):246. PubMed ID: 27633880 [TBL] [Abstract][Full Text] [Related]
8. A comparison of hematologic toxicity profiles after heated intraperitoneal chemotherapy with oxaliplatin and mitomycin C. Votanopoulos K; Ihemelandu C; Shen P; Stewart J; Russell G; Levine EA J Surg Res; 2013 Jan; 179(1):e133-9. PubMed ID: 22480844 [TBL] [Abstract][Full Text] [Related]
9. Population pharmacokinetics of peritoneal, plasma ultrafiltrated and protein-bound oxaliplatin concentrations in patients with disseminated peritoneal cancer after intraperitoneal hyperthermic chemoperfusion of oxaliplatin following cytoreductive surgery: correlation between oxaliplatin exposure and thrombocytopenia. Chalret du Rieu Q; White-Koning M; Picaud L; Lochon I; Marsili S; Gladieff L; Chatelut E; Ferron G Cancer Chemother Pharmacol; 2014 Sep; 74(3):571-82. PubMed ID: 25053386 [TBL] [Abstract][Full Text] [Related]
10. Cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy with oxaliplatin for peritoneal carcinomatosis arising from colorectal cancer. Gervais MK; Dubé P; McConnell Y; Drolet P; Mitchell A; Sideris L J Surg Oncol; 2013 Dec; 108(7):438-43. PubMed ID: 24018983 [TBL] [Abstract][Full Text] [Related]
11. Does early post-operative intraperitoneal chemotherapy (EPIC) for patients treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC) make a difference? Tan GH; Ong WS; Chia CS; Tham CK; Soo KC; Teo MC Int J Hyperthermia; 2016 May; 32(3):281-8. PubMed ID: 26862667 [TBL] [Abstract][Full Text] [Related]
12. Trends in cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for the treatment of synchronous peritoneal carcinomatosis of colorectal origin in the Netherlands. Razenberg LG; van Gestel YR; Creemers GJ; Verwaal VJ; Lemmens VE; de Hingh IH Eur J Surg Oncol; 2015 Apr; 41(4):466-71. PubMed ID: 25680955 [TBL] [Abstract][Full Text] [Related]
13. The American Society of Peritoneal Surface Malignancies evaluation of HIPEC with Mitomycin C versus Oxaliplatin in 539 patients with colon cancer undergoing a complete cytoreductive surgery. Prada-Villaverde A; Esquivel J; Lowy AM; Markman M; Chua T; Pelz J; Baratti D; Baumgartner JM; Berri R; Bretcha-Boix P; Deraco M; Flores-Ayala G; Glehen O; Gomez-Portilla A; González-Moreno S; Goodman M; Halkia E; Kusamura S; Moller M; Passot G; Pocard M; Salti G; Sardi A; Senthil M; Spiliotis J; Torres-Melero J; Turaga K; Trout R J Surg Oncol; 2014 Dec; 110(7):779-85. PubMed ID: 25088304 [TBL] [Abstract][Full Text] [Related]
14. Current practice in cytoreductive surgery and HIPEC for metastatic peritoneal disease: Spanish multicentric survey. Morales-Soriano R; Esteve-Pérez N; Segura-Sampedro JJ; Cascales-Campos P; Barrios P; Eur J Surg Oncol; 2018 Feb; 44(2):228-236. PubMed ID: 29242018 [TBL] [Abstract][Full Text] [Related]
15. Hyperthermic intraperitoneal chemotherapy + early postoperative intraperitoneal chemotherapy versus hyperthermic intraperitoneal chemotherapy alone: assessment of survival outcomes for colorectal and high-grade appendiceal peritoneal carcinomatosis. Lam JY; McConnell YJ; Rivard JD; Temple WJ; Mack LA Am J Surg; 2015 Sep; 210(3):424-30. PubMed ID: 26051744 [TBL] [Abstract][Full Text] [Related]
16. Optimization of hyperthermic intraperitoneal chemotherapy with oxaliplatin plus irinotecan at 43 degrees C after compete cytoreductive surgery: mortality and morbidity in 106 consecutive patients. Elias D; Goere D; Blot F; Billard V; Pocard M; Kohneh-Shahri N; Raynard B Ann Surg Oncol; 2007 Jun; 14(6):1818-24. PubMed ID: 17356950 [TBL] [Abstract][Full Text] [Related]
17. Cytoreductive Surgery Combined with Hyperthermic Intraperitoneal Chemotherapy with Oxaliplatin Increases the Risk of Postoperative Hemorrhagic Complications: Analysis of Predictive Factors. Charrier T; Passot G; Peron J; Maurice C; Gocevska S; Quénet F; Eveno C; Pocard M; Goere D; Elias D; Ortega-Deballon P; Vaudoyer D; Cotte E; Glehen O Ann Surg Oncol; 2016 Jul; 23(7):2315-22. PubMed ID: 26920385 [TBL] [Abstract][Full Text] [Related]
18. Complete cytoreductive surgery plus intraperitoneal chemohyperthermia with oxaliplatin for peritoneal carcinomatosis of colorectal origin. Elias D; Lefevre JH; Chevalier J; Brouquet A; Marchal F; Classe JM; Ferron G; Guilloit JM; Meeus P; Goéré D; Bonastre J J Clin Oncol; 2009 Feb; 27(5):681-5. PubMed ID: 19103728 [TBL] [Abstract][Full Text] [Related]
19. Cytoreductive surgery and HIPEC for peritoneal carcinomatosis. A review on morbidity and mortality. Halkia E; Kopanakis N; Nikolaou G; Spiliotis J J BUON; 2015 May; 20 Suppl 1():S80-7. PubMed ID: 26051337 [TBL] [Abstract][Full Text] [Related]
20. Enterocutaneous fistula in patients with peritoneal malignancy following cytoreductive surgery and hyperthermic intraperitoneal chemotherapy: Incidence, management and outcomes. Valle SJ; Alzahrani N; Alzahrani S; Traiki TB; Liauw W; Morris DL Surg Oncol; 2016 Sep; 25(3):315-20. PubMed ID: 27566038 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]